This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Yourgene Health Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Yourgene Health.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth21.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Yourgene Health Plc (LON:YGEN) Shares Could Be 34% Above Their Intrinsic Value Estimate

Sep 22
Yourgene Health Plc (LON:YGEN) Shares Could Be 34% Above Their Intrinsic Value Estimate

Is There An Opportunity With Yourgene Health Plc's (LON:YGEN) 35% Undervaluation?

Apr 15
Is There An Opportunity With Yourgene Health Plc's (LON:YGEN) 35% Undervaluation?

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Yourgene Health Plc's (LON:YGEN) CEO For Now

Sep 22
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Yourgene Health Plc's (LON:YGEN) CEO For Now

Estimating The Intrinsic Value Of Yourgene Health Plc (LON:YGEN)

Aug 07
Estimating The Intrinsic Value Of Yourgene Health Plc (LON:YGEN)

Does This Valuation Of Yourgene Health Plc (LON:YGEN) Imply Investors Are Overpaying?

Feb 25
Does This Valuation Of Yourgene Health Plc (LON:YGEN) Imply Investors Are Overpaying?

What Did Yourgene Health's (LON:YGEN) CEO Take Home Last Year?

Jan 27
What Did Yourgene Health's (LON:YGEN) CEO Take Home Last Year?

What Kind Of Shareholders Hold The Majority In Yourgene Health Plc's (LON:YGEN) Shares?

Dec 22
What Kind Of Shareholders Hold The Majority In Yourgene Health Plc's (LON:YGEN) Shares?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Yourgene Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

AIM:YGEN - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/202230-8-5-3N/A
6/30/202234-5-3-1N/A
3/31/202238-2-11N/A
12/31/202133-6-3-1N/A
9/30/202128-10-5-3N/A
6/30/202123-11-6-3N/A
3/31/202118-12-8-4N/A
12/31/202018-8-6-3N/A
9/30/202017-4-5-2N/A
6/30/202017-3-4-2N/A
3/31/202017-2-3-2N/A
12/31/2019151-4-2N/A
9/30/2019135-4-2N/A
6/30/2019114-4-3N/A
3/31/201993-5-4N/A
12/31/20188-2-7-6N/A
9/30/20187-8-9-8N/A
6/30/20187-9-9-9N/A
3/31/20186-9-10-10N/A
12/31/20175-9-9-9N/A
9/30/20174-9-9-9N/A
6/30/20174-9-9-8N/A
3/31/20173-8-8-8N/A
12/31/20163-10-8-8N/A
9/30/20163-11-8-8N/A
6/30/20163-12N/A-7N/A
3/31/20162-12N/A-7N/A
9/30/20151-7N/A-5N/A
3/31/20150-7N/A-5N/A
2/28/20140-2N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if YGEN's forecast earnings growth is above the savings rate (1.4%).

Earnings vs Market: Insufficient data to determine if YGEN's earnings are forecast to grow faster than the UK market

High Growth Earnings: Insufficient data to determine if YGEN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if YGEN's revenue is forecast to grow faster than the UK market.

High Growth Revenue: Insufficient data to determine if YGEN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if YGEN's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.